source
- Overseas MDMA and psilocybin makers eye U.S. market as regulatory landscape easesCompanies that produce MDMA and psilocybin for patients abroad are turning their attention to the United States, hoping to leverage experience gained under more permissive foreign rules. Rising pol…
- MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighterDespite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.Fierce Biotech · 4h ago↗ source
- Taiho and Cullinan report positive Phase 3 results for zipalertinib in EGFR exon 20 insertion lung cancer